SOLASTA Bio, a UK agritech specialising in the next generation of green insecticides has secured a further round of investment totalling £4 million to scale up the development of its unique nature-inspired pesticides, the first of their kind to be developed worldwide.

Oxford Innovation EIS Growth Fund alongside OION angel investors, have invested in the £1.2 million oversubscribed funding round for OSSTEC, the orthopaedics company developing bone healing implants.

Its patented platform technology, proven over 8 years of research and development at Imperial College London, reduces implant loosening and bone loss post-surgery. OSSTEC’s world leading team combining engineers and surgeons, has developed the first fully porous implants to stimulate long-term bone growth.

A Newcastle-based company has raised over £ 1.85 million of funding to help its quest to save more lives through better testing for prostate cancer.

The funding includes £500,000 investment from the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures alongside investment from Prostate Cancer Research together with and investment of £250,000 from JR Holding ASI, and £305,000 from angel investors. On top of this investment Innovate UK awarded the company a grant of £750,000 to develop its disease screening activities.

The SABI has successfully closed its pre-seed investment round, securing €150,000 from a group of industry focused investors. 

QV Bioelectronics, creators of an innovative surgically implanted Electric Field Therapy (EFT) device for the treatment of brain tumours, has been awarded a £860,000 grant under the Combined Investor Partnerships Award. This follow a successful £2m Pre-Series A fundraising round in January 2023, which included a number of angel investors. 

The award from Innovate UK takes the total amount of grant funding awarded to QV to £1.8m, which includes an ongoing Innovate UK Biomedical Catalyst Award and previous support from the National Institute for Health Research (NIHR) and Innovate UK SMART.

Antiverse Ltd, a biotechnology company developing a computational antibody drug discovery platform, has closed a $3 million investment round that will enable further development of its AI-driven drug discovery platform.

Eventum Orthopaedics, a medtech company which has developed a device that could improve the success of knee replacement surgery has raised £2.5m in a Series A funding round.

Venture Capital firm, QVentures, has made a pre-seed fund investment into Presentient Technologies, a software platform developing innovative tools for companies running clinical trials. The funding round was led by QVentures with participation from Episode1 and industry angels.

Belfast-based cancer diagnostics company GenoME Diagnostics has closed a £1.4 million funding round with investment from QUBIS, the commercialisation arm of Queen’s University, Co-Fund NI (managed by Clarendon Fund Managers) and Deepbridge Capital.

Archangels-backed dental imaging technology company Calcivis is setting its sights on US growth having secured pre-market approval (PMA) from the US Food and Drug Administration (FDA).

CanSense - a Swansea company which has developed a blood test that aims to save lives by diagnosing bowel cancer at an early stage - has raised £1.5m from Mercia, the Development Bank of Wales and liquid biopsy company Nonacus.

CanSense’s test, which combines laser spectroscopy with artificial intelligence, is faster, less expensive and less invasive than a colonoscopy procedure and more acceptable for patients than a faecal blood detection kit. It could help detect bowel cancer at an early stage when it is much easier to treat and the chance of survival is much higher.

YFM has led a £10m investment into healthtech company DrDoctor along with Ananda Impact Ventures and 24 Haymarket

DrDoctor was founded in 2012 by Tom Whicher, Rinesh Amin and Perran Pengelly and provides digital care solutions to increase communication and engagement between patients and clinicians, managing 25 per cent of NHS outpatient appointments.